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analogs to probe the biological function of protein farnesy
lation.
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FARNESYL PYROPHOSPHATE ANALOGS

attachment of tWo geranylgeranyl groups to paired carboXyl
terminal cysteines in members of the Rab family of GTP
binding proteins (10). These proteins terminate in a CC or

This application claims priority from provisional appli

CXC motif.

cation 60/112,208, ?led on Dec. 15, 1998.

A number of basic issues pertaining to the biological
function of protein isoprenylation, and the contribution of
lipid modi?cation in general, remain to be ansWered. While

FIELD OF THE INVENTION

The present invention relates to farnesyl pyrophosphate
analogs and their use in modulating cellular chemistry. More
speci?cally, the invention relates to unsubstituted and sub

stituted anilinogeranyl pyrophosphates (AGPP), unsubsti

farnesylation of Ras is absolutely required for its biological
10

tuted and substituted benZyloXyalkylisoprenyl
pyrophosphates, the processes of making the same, inter

effects and membrane localiZation, it is unknoWn Whether
the prenyl group functions as a hydrophobic membrane

association signal (11—16) or by targeted protein-protein
recognition (17,18). The functional signi?cance of protein
farnesylation versus geranylgeranylation to the biological
activity of prenylated proteins is also unknoWn. Studies
employing inhibitors of FTase have highlighted the impor

mediates for use in the process of making the same, and the

methods of using the EFF analogs in substitution for farnesyl
pyrophosphate (FPP) or as farnesyl transferase inhibitors

tance of isoprenylation to the membrane association and

(FTIs).

activity of the Ras family of signal transduction proteins.
HoWever, inhibition of protein prenylation precludes relat

BACKGROUND OF THE INVENTION

ing the effects of many of the doWnstream events such as

Farnesyl pyrophosphate 1 (FPP) and its C2O homolog,
geranylgeranyl pyrophosphate (GGPP) are isoprenoids that

further modi?cation of the target protein by palmitoylation,
proteolysis and carboXymethylation to the biological func

are involved in a number of cellular processes including

tion of Ras.
EXtensive research studies have established an important
contribution of aberrant Ras function to human carcinogen

cholesterol biosynthesis, glycoprotein biosynthesis, vitamin
and cofactor synthesis and protein prenylation. Recently, the
enZyme farnesyltransferase (FTase) Which can utiliZe FPP or
GGPP as a substrate depending on the nature of the [3
subunit, has attracted considerable interest as a possible

25

esis (88, 89) Consequently, there is considerable interest in
the development of inhibitors of Ras function for use in
cancer treatment. Since Ras function is absolutely dependent

target for the design of chemotherapeutic agents.
An area of interest is the continued search for proteins that
are post-translationally modi?ed in cells as part of normal

on lipid modi?cation and tight association With the plasma
membrane, the development of drugs that block Ras mem
brane association has attracted the greatest interest (89—91).

metabolism. Farnesylation has been shoWn to be required
for the normal function of various proteins including Ras.

opment of inhibitors of post-translational processing of Ras

FTase has proven to be a biochemical target for the devel

that act as potent anti-Ras drugs.

Mutated forms of the cellular Ras genes are among the
most common genetic abnormalities in human cancer,

occurring in 30% of all neoplasms. This frequency indicates

35

Several general approaches have been employed in the
identi?cation and development of speci?c FTase inhibitors

(revieWed in 88). First, high throughput random screens

an important role for aberrant Ras function in carcinogenesis
(1). Ras proteins are synthesiZed as cytosolic precursors
Which localiZe to the inner lea?et of the plasma membrane
only after undergoing a series of Well de?ned posttransla
tional modi?cations
The ?rst and obligatory step in this

have been used to identify natural or library compounds that
inhibit the ability of FTase to catalyZe the addition of
farnesyl to recombinant Ras in vitro. Second, Ras CaaX
tetrapeptide sequences alone are suf?cient to signal modi

processing is the transfer by protein farnesyltransferase
(FTase) of the 15-carbon isoprene farnesyl from farnesylpy

FTase activity in vitro. Therefore, a variety of CaaX-based

?cation by farnesylation and can serve as potent inhibitors of

peptidomimetic compounds have been synthesiZed.

rophosphate (FPP) to a cysteine residue located at the Ras
C-terminus via a thioether linkage (2,3). This Cys residue

forms part of the prenylation recognition sequence, CAAX
(Where Ais an aliphatic residue and X is most often Met, Ser,
or Gln), present in all Ras proteins
Prenylation is
folloWed by proteolytic removal of the COOH-terminal
tripeptide and carboXymethylation of the noW terminal,
prenylated cysteine
These modi?cations render the
C-terminus hydrophobic, Which is thought to promote the
association of these proteins With the plasma membrane.

45

compounds. HoWever, the structural requirements of the
prenyl group have not been uncovered.
The initial characteriZation of FTIs Was done in ?broblast

model systems transformed by oncogenic H-Ras (92, 93).
These studies clearly shoWed that FTIs can potently and

speci?cally inhibit H-Ras farnesylation, Without affecting
the modi?cation of geranylgeranylated proteins. FTI inhi
bition of H-Ras processing correlated directly With inhibi

Studies employing site-directed mutants Within the Ras
CAAX motif (5,6) or inhibitors of 3-hydroXyl-3

methylglutaryl CoA reductase (7), the rate limiting enZyme
in isoprenoid biosynthesis, have demonstrated that isopre
nylation is required for Ras proteins to become membrane

tion of H-Ras-induced signaling, morphologic and groWth
55

Three distinct enZymes responsible for protein isopreny

carrying the transgene (96, 97). An unexpected, but desired,

lation have been isolated and biochemically characteriZed
(2). In addition to FTase, tWo geranylgeranyl-transferases
(GGTases) have been isolated and have been shoWn to

aspect of these studies is the apparent lack of normal cell

toXicity. This Was uneXpected because farnesylation is
required for normal Ras function, Which is critical for
normal cell viability (97). The reason(s) for the relative

modify speci?c protein substrates. While the CAAX
GGTase (also knoWn as GGTase-1) geranylgeranylates pro
teins Which end in a CAAL sequence, Where C is cysteine,

transformation (94). Similar dramatic results Were seen in in

vivo tumor models using Ras-transformed rodent cells
groWn as Xenografted tumors in nude mice (95), and in viral
H-Ras transgenic mice in Which salivary and mammary
tumors occur stochastically in a high percentage of mice

associated and to induce cellular transformation.

A is usually an aliphatic amino acid, and L is leucine (8,9),
the Rab GGTase (also knoWn as GGTase-2) catalyZes the

Consequently, the potent and selective FTIs identi?ed to
date include a diverse collection of structurally unrelated

65

resistance of normal cells to FTIs is presently not knoWn.

Because of previous ?nding that FTIs Were capable of
inhibiting Ras transformation in animal model systems, and

US 6,284,910 B1
4

3
because of the Widespread tendency to vieW FTIs as Ras

It is accordingly an aspect of the invention to provide a

inhibitors rather than FTase inhibitors, many investigators

FPP analogs Which Would be ef?ciently utiliZed by FTase,
alloW for further derivatiZation for high speci?c activity

assumed that human tumors cells that contained mutated Ras
proteins Would be more sensitive to FTI action than those
that did not. HoWever, studies have shoWn that ras mutation

labeling or cross linkers to be designed, and that Would be

recogniZed and transferred to FTase substrate proteins With
an activity approaching that of FPP. Such FPP mimetic

status is not predictive of FTI sensitivity (98). Indeed, it is
clear that these drugs interfere With the processing of other

molecules can interfere With other cellular events, While
acting as non FTI anti-Ras molecules.

farnesylated proteins in addition to Ras. There is noW
evidence that FTIs may block Ras transformation, in part, by
inhibiting the function of other farnesylated proteins, one or
more of Which may represent the critical target for FTI

FPP analogs of the invention also inhibit the function of
FTase.

It is accordingly another aspect of the invention to provide
FPP analogs that are inhibitors of farnesyl transferase and
therefore affect intracellular processes involving the transfer
of farnesyl to intracellular proteins essential to the function

action (87, 99, 100).
It is clear that the cellular mechanism by Which FTIs eXert

their biological activity is incompletely understood (88).
TWo central issues appear that must be addressed before the
biochemical mechanism by Which FTIs function can be
understood. First, it is necessary to understand the biological

15

Conceptually, FPP can be vieWed as a four-section mol

ecule. The ot-isoprene and the pyrophosphate moiety remain

signi?cance of the isoprenoid lipid in the conteXt of the
function of a fully processed prenyl protein. For FTIs, the
natural targets for this analysis are the Ras oncoproteins.
Second, as outlined above, it is likely that FTIs inhibit the
farnesylation of additional cellular proteins, many of Which

invariant in all of the FPP analogs of the present invention
because an allylic pyrophosphate is essential for FTase

catalyZed transfer to protein substrate (117).
The structure of FPP:

remain to be identi?ed, and are likely to depend upon
prenylation for some aspect of their function. Therefore, the

key to applying FTase-based pharmacological intervention

ing of those intracellular proteins.

25

is a thorough understanding of the in vivo farnesylation
pathWays. Knowledge of the complete array of cellular
protein substrates and substrate speci?cities for FTase and
the cellular role of the isoprenoid moiety Will be critical in
improving the design and action of effective FTIs.
Prenyl analogs and FTIs have contributed to the under
standing of prenylation and such information is useful in the

)\/\\)\/\\)\/\\OPP
(Jo-isoprene

[5-isoprene

ot-isoprene

Aniline

Isoprene

Invariant

OT OBZ

or Alkylene

Isoprene

Pyrophosphate,

design and evaluation of therapeutics. The mechanism
underlying FTI action is of interest for several reasons. The

action of the drug is likely to be secondary to the speci?c
inhibition of Ras farnesylation, suggesting that additional
farnesylated proteins yet to be identi?ed or assigned a
cellular function play a critical role in the biology of
transformation (90). Second, several FTIs are currently
entering phase I trials as anticancer drugs in humans and
rational clinical development Will depend on understanding
the biochemical basis for their inhibition of cell groWth.

35

isoprene unit in compounds according to the invention,
Wherein aniline may be unsubstituted or substituted, OBZ is
a benZyloXy group, Which is unsubstituted or substituted as

indicated in Formulae I-II beloW, and alkylene is an alkylene
linking group having 1 to 10 carbon atoms.
BRIEF DESCRIPTION OF THE DRAWINGS

SUMMARY OF THE INVENTION

The present invention provides for the preparation and
functional characteriZation of unsubstituted anilinogeranyl

The captions beloW the ot-, [3-, and uu-isoprene units of
FPP above represent the general substitutions made for the

FIG. 1. Structure of farnesylpyrophosphate 1, gera
45

nylgeranylpyrophosphate 2, 8-anilinogeranyl pyrophos
phate (AGPP) 3a, p-iodo-8-anilinogeranyl pyrophosphate

pyrophosphate (AGPP), substituted anilinogeranyl

(AGPP) 3b.

pyrophosphate, unsubstituted and substituted benZyloXy

FIG. 2. Differential Inhibition of Farnesyltransferase and
CAAX Geranylgeranyltransferase by AGPP. The assay miX
tures contained (in a ?nal volume of 25 pl) various compo

alkylisoprenyl pyrophosphate, and pharmaceutically accept
able salts thereof, Which meet the criteria set forth for FPP

analogs (i.e. FTase substrates and inhibitors) in the Back

nents as described in “Experimental Procedures”. After

ground of the Invention. AGPP and other FPP analogs of the
invention are recogniZed and transferred to Ras by FTase
With in vitro kinetic properties that are indistinguishable

incubation for 15 min at 37° C., the amount of [3H]prenyl

from those of FPP. AGPP can be modi?ed by iodination

group transferred to the appropriate protein substrate [H-Ras
(CVLS) for FTase and H-Ras (CVLL) for CAAX GGTase]
55

Without signi?cantly altering these properties, alloWing syn

Was measured by precipitation With ethanol-HCl. The assays
contained 10 ng recombinant rat FTase, 5 pM H-Ras, and 0.6

pM [3H]FPP (33,000 dpm/pmol) or 100 ng recombinant rat
CAAX GGTase, 5 pM H-Ras CVLL, and 1 pM [3H]GGPP
(33,000 dpm/pmol) and the indicated concentration of unla

thesis of additional analogs. Other analogs of FPP Wherein
the uu-isoprenyl moiety is replaced by either a functionaliZed
aniline or a functionaliZed benZyloXy group may be synthe

siZed by alternate routes. Finally, the present invention

beled AGPP. The 100% of control values Were 1.1 and 5.5

reveals that AGPP and other FPP analogs of the invention

pmol of [3H]farnesyl or [3H]geranylgeranyl transferred per

are poorly recogniZed by, and transferred to, substrate by

tube. Each value is the average of duplicate incubations and

GGTase I and are neither substrates for, nor inhibitors of,

is representative of tWo separate experiments.
FIG. 3. Inhibition of Farnesyltransferase by AGPP and

squalene synthase, suggesting a high degree of selectivity
toWard FTase in vivo. Thus, the present invention provides
for a method of using AGPP as a substrate for FTase in the

prenylation of Ras.

65

I-AGPP. The enZymatic activity Was measured in the pres
ence of the various concentrations of either AGPP or
I-AGPP as described in FIG. 3. The 100% control values

US 6,284,910 B1
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Were 1.9 and 2 pmol. Each value is the average of duplicate

DETAILED DESCRIPTION OF THE
INVENTION

incubations and is representative of three separate experi
ments.

The farnesyl pyrophosphate analogs of this invention are

FIG. 4. Transfer of Anilinogeranyl from [3H]AGPP to

p21HH'mS by Farnesyltransferase. (A) Each reaction con
tained 1 pM [3H]AGPP (37,400 dpm/pmol) and 10 ng of

useful as substrates for FTase, and in particular for FTase
mediated isoprenylation of proteins such as the Ras protein.

recombinant FTase in the absence (triangles) or presence

The farnesyl pyrophosphate analogs of the invention are
also useful as farnesyl transferase inhibitors (FTIs).

(circles) of 5 pM p2lHa'ms Duplicate samples Were incu
bated for the indicated times at 37° C., and ethanol-HCl

The farnesyl pyrophosphate analogs of this invention may
be prepared in free base form, or they may be prepared in the
form of pharmaceutically acceptable salts according to the
conventional practice in the pharmaceutical arts. Likewise,
they can be prepared in pharmaceutically acceptable form in
combination With carriers, adjuvants, excipients and the like.

precipitated radioactivity Was measures as described under

“Experimental Procedures”. The inset shoWs the migration
of on a 12.5% SDS-polyacrylamide gel of an aliquot from
the reaction carried out for 1 hr in the presence (+) or

absence (—) of p2lHa'ms. The gel Was treated With Amplify
solution (Amersham), dried, and exposed to Kodak
X-OMAT AR ?lm for 2 days at —70° C. The migration of
molecular Weight markers placed in a adjacent lane is
shoWn. (B) The AGPP substrate saturation curve for FTase
Was determined by varying the amount of [3H]AGPP in the

15

The dosages of the compounds, their pharmaceutically
acceptable salts and compositions containing them may be
determined by conventional clinical methods in the art.

The farnesyl pyrophosphate analogs according to this
invention may be employed for the treatment of human and

standard reaction described above. Assays Were carried out

non-human patients in Which modulation of farnesyl pyro

in duplicate for 30 min at 37° C., and the ethanol-HCl

precipitable radioactivity measured. The data is representa
tive of three independent experiments.

phosphate or FTase inhibition is desired. As farnesyl pyro
phosphate is involved in a number of cellular processes

FIG. 5. [3H]AGPP and [3H]FPP are Bound and Trans

biosynthesis, vitamin and cofactor synthesis and protein

ferred With Comparable Af?nities by Farnesyltransferase.
Farnesyltransferase (10 ng) Was incubated in a ?nal volume
of 25 pl in the presence of 1.0 pM [3H]AGPP or [3H]FPP and
5 pM Wild-type p21HH'mS. After incubation for 30 min at 37°
C., the amount of [3H]prenyl transferred to p2lHa'ms Was
determined as described under “Experimental Procedures”.
Each value is the average of duplicate incubations and is

including cholesterol biosynthesis, glycoprotein
25

lular proteins such as Ras is implicated, such as cancer.

representative of ?ve separate experiments.

Recently, the enZyme farnesyltransferase (FTase) Which

FIG. 6. Identi?cation of [3H]AGPP-Derived Radioactive
Material Transferred to p2lHa'ms. An aliquot from a stan
dard FTase reaction Was subjected to Pronase E digestion as
described under “Experimental Procedures”. The labeled
products, extracted With 1-butanol, Were analyZed on C18

prenylation, the compounds of the present invention are
useful for affecting such cellular processes and disease states
caused thereby. Also, as FTase is involved in farnesylation
of important intracellular proteins such as Ras, the com
pounds of the present invention are useful for treating
disease states in Which farnesylation of important intracel

can utiliZe FPP or GGPP as a substrate, depending on the

nature of the [3 subunit, has attracted considerable interest as
35

a possible target for the design of chemotherapeutic agents.
The present invention thus contemplates a method of treat

ing conditions that are affected by FPP and its analogs.
The compounds of this invention are illustrated by general

reverse-phase TLC plates developed in acetonitrile:Water
:acetic acid (75:25 :1). Radioactive Zones Were located With
a Bioscan Imaging System 200-IBM. The arroWs indicate

the position of authentic F-Cys, GG-Cys, and AG-Cys. O
and F denote the positions of the origin and solvent front.
The data shoWn are representative of tWo independent

(1)

experiments.
FIG. 7. Inhibition of Squalene Synthase by AGPP. The
initial rates of squalene synthase activity Were determined
from bovine brain microsomal preparations in the presence
of the indicated concentration of unlabeled AGPP (?lled
squares) or unlabeled FPP (open triangles) under the in vitro
conditions described in “Experimental Procedures.” Crude

45

Wherein the phenyl ring is unsubstituted or substituted.

bovine brain microsomes and 0.05 mM [3H]FPP (105 cpm/

Suitable substituents for the phenyl ring are, for example, H,

pmol) and unlabeled AGPP and FPP Were added at the
indicated concentrations and incubated for 30 min. at 37° C.
The reactions Were terminated With 40% (Wt/vol) KOH and

halo, NO2, NH2, NHR7, N(R7)2, N(R7)3+, N3, OH, OR7 and
optionally substituted C1 to C8 alkyl. R7 is CM—C8 alkyl (e.g.

95% ethanol. Authentic carrier squalene (20 pg) Was added
and the reactions extracted With petroleum ether. The

methyl, ethyl, i-propyl, n-propyl, n-butyl, i-butyl, s-butyl,
55

bations and is representative of three separate experiments.
FIG. 8. Progress Curves for Transfer of FPP and Analog
Pyrophosphates to Dansyl-GCVLS by FTase. The reaction is
monitored for ?uorescence intensity at 505 nm With exci

tation at 340 nm. (a) FPP, (b) AGPP, (c)

8-(penta?uoroaniline)geranyl pyrophosphate, (d) blank.
FIG. 9. AGPP Rescues the Biological Activity of Onco
Maturation Kinetics Relative to FPP.

acetyl, propanoyl, etc.). G4 is OPP, OR8, or S-linked cys
teine (Which may be in the R, S or racemic con?guration).
And R8 is a suitable hydroxy protecting group.

amount of labeled lipid formed Was measured by scintilla
tion counting. Each value is the average of duplicate incu

genic H-Ras in Isoprenoid Depleted Oocytes With Delayed

t-butyl, n-pentyl, etc.) or C1—C8 alkanoyl (e.g. formyl,

65
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n is an integer of 0 to 14, inclusive;

R6 is H or alkyl.

Throughout this description, OPP is the pyrophosphate
group:

R2
O

O

|

I

R1

N

\

\

OPP

R3
10

In general, according to the present invention, alkyl is a
C1 to C8 alkyl substituent group. Examples of alkyl are

Wherein

methyl, ethyl, i-propyl, n-propyl, n-butyl, t-butyl, s-butyl,
i-butyl, pentyl, etc. Suitable optional substitutents for such

15

alkyl groups may be one or more substituents such as amine,

R1, R2, R4, and R5 are H or F;
R3 is H, NO2, I, F or N3; and

R6 is H, methyl or ethyl.
Another preferred compound of formula I is represented
by formula 11:

alkyl amine, dialkylamine, nitrile, and hydroxy. Preferred
substituted alkyl groups are hydroxymethyl, hydroxyethyl,

aminomethyl, aminoethyl, (NC)CH2—, and (NC)
CH2CH2—.

11

A preferred embodiment of the above compounds of
formula I is illustrated by formula II:

<11)

R1
25

R1

I|K6

R.

Owed

R3

R5

COO

Wherein R1—R6 are de?ned above in formula I and the

moiety:

R4

Wherein R1, R2, R3, R4, and R5 are, for example, H, halo,

35

COO

NO2, NH2, NHR7, N(R7)2, N(R7)3+, N3, OH, OR7, C1 to C8
alkyl, amino C1—C8 alkyl, hydroxy C1—C8 alkyl, nitrile
C1—C8 alkyl, etc. G1, G2, G3, and G4 are de?ned in formula
I. The variable m is an integer of 0 to 5. R7 is C1—C8 alkyl

(e.g. methyl, ethyl, i-propyl, n-propyl, n-butyl, i-butyl,
s-butyl, t-butyl, n-pentyl, etc.) or C1—C8 alkanoyl (e.g.
formyl, acetyl, propanoyl, etc.) etc.

is the aforementioned S-linked cysteine, Which may be in the
R, S or racemic con?guration, more preferably in the

Another preferred embodiment of compounds of formula
I is illustrated by formula III:

cysteine).

S-con?guration (i.e. derived from the naturally occurring
45

(III)

R1

R2

S-con?guration (compound 11a).

IIKG

Even more particularly preferred compounds of formula

\
\
OPP
NM

IV include:

R3

55

Wherein R1, R2, R3, R4, and R5 are, for example, H, halo,

NO2, NH2, NHR7, N(R7)2, N(R7)3+, N3, OH, OR7, C1—C8
alkyl, amino C1—C8 alkyl, hydroxy C1—C8 alkyl, nitrile
C1—C8 alkyl, etc. R7 is C1—C8 alkyl (e.g. methyl, ethyl,
i-propyl, n-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl,
etc.) or C1—C8 alkanyl (e.g. formyl, acetyl, propanoyl, etc.)

phosphate;

(5) 8-(4-aZido-2,3,5,6-tetra?uoroaniline)-3,7-dimethyl-2,6
octadiene pyrophosphate; and

(6) 8-(N-ethyl-4-aZido-2,3,5,6-tetra?uoroaniline)-3,7
dimethyl-2,6-octadiene pyrophosphate.

n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl,
An even more preferred embodiment of compounds of

formula III is represented by formula IV:

(1) 8-aniline-3,7-dimethyl-2,6-octadiene pyrophosphate
(AGPP);
(2) 8-(4-nitroaniline)-3,7-dimethyl-2,6-octadiene pyrophos
phate;
(3) 8-(4-iodoaniline)-3,7-dimethyl-2,6-octadiene pyrophos
phate;
(4) 8-penta?uoroaniline-3,7-dimethyl-2,6-octadiene pyro

etc., and alkyl is C1 to C8 alkyl, for example methyl, ethyl,
etc.

Preferred compounds of formula 11 are those in Which,
R1—R6 are H and the S-linked cysteine is in the

65

Another preferred embodiment of the compounds of
formula I is exempli?ed by the compounds of formula V:

US 6,284,910 B1
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as methyl, ethyl, i-propyl, n-propyl, i-butyl, n-butyl, s-butyl,
t-butyl, etc. The variable s is an integer from 1 to 5.

(V)

Another preferred embodiment of compounds of formula

R4

II includes the compounds of formula IX:
R3

R5

(IX)

R2

0

Wow

ILMOVWOPP
R6

R1
10

wherein R1—R5 are as de?ned in formula I, p is an integer
from 1 to 10 and OPP stands for the pyrophosphate group.
Particularly preferred compounds of formula V are eXem

R5

pli?ed by formula VI: Wherein R1—R5 are as in formula V,
above; q is an integer of 1 to 5, inclusive; and OPP is the
Wherein R1—R5 are is as de?ned in formula I, t is an integer

(VI)

from 1 to 5 and R6 is hydrogen or C1—C8 alkyl.
Another preferred embodiment of compounds of formula
I includes compounds of formula X:

R4

R3

R5

R2

0

(X)

WOPP

R4

25

R1

pyrophosphate group.
Particularly preferred compounds of formula VI include
compounds exempli?ed by formula VII:
(VII)

0

R2

N

I WON

R6

Wherein R1—R6 are as de?ned in formula I, above and u is
an integer number 1 to 10.
Another aspect of the invention relates to a novel oligo
ether of formula XI:

R5

R2

R5

R1

R4

R3

R3

Mow

(XI)

HOMOVWOPP

R1

Wherein R3 is as de?ned in formula VI other than H; and R1,
R2, R4, and R5 are as de?ned in formula VI; r is an integer
of 1 to 5, inclusive; and OPP is the pyrophosphate group.

Wherein v is an integer from 1 to 10, inclusive; and OPP is

the pyrophosphate group.

Particularly preferred compounds of formula V have been

synthesiZed, including:

45

Another aspect of the invention relates to compounds of
the formula XII:

6-benZyloXy-3-methyl-2-heXene pyrophosphate (12);
7-benZyloXy-3-methyl-2-heptene pyrophosphate (13);
8-benZyloXy-3-methyl-2-octene pyrophosphate (14);

(XII)

9-benZyloXy-3-methyl-2-nonene pyrophosphate; and

HO

10-benZyloXy-3-methyl-2-decene pyrophosphate.

WON)
W

Another preferred embodiment of compounds of formula
I is exempli?ed by the compounds of formula VIII:

Wherein W is an integer of 1 to 10, inclusive and OPP is the
55

pyrophosphate group.

(VIII)

Another aspect of the claimed invention relates to allylic
diols of formula XIII:

O/\/{ WON,

(XIII)

R1
R2

0

R3

R5
R4
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Wherein R1—R5 are as de?ned in formula I, preferably NO2,
N3, NH3, halo, such as F, Cl, Br and I, 1—8 carbon alkyl such

Wherein Z is an integer of 1 to 14.

Compounds of formula I possess a pyrophosphate group
Which is acidic under physiologic conditions. The com

US 6,284,910 B1
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12

pounds of the invention may therefore be formulated in the
form of free acid. They may also be formulated as pharma

sitions of this invention include aqueous solutions compris

ing compounds of this invention and pharmacologically

ceutically acceptable salts by conventional methods Well

acceptable carriers, e.g., saline, at a pH level, e.g., 7.4. The
solutions may be introduced into a patient’s intramuscular
knoWn in the art, such as by combining an acidic compound
of the present invention With a physiologically tolerated 5 blood-stream by local bolus injection.
When a compound according to this invention is admin
base. Such bases include alkali or alkaline earth metal
istered into a human subject, the daily dosage Will normally
hydroxides such as NaOH, KOH, LiOH, etc. Such bases also
be determined by the prescribing physician With the dosage
included organic amines such as dibenZylethylenediamine,

trimethylamine, piperidine, pyrrolidine, benZylamine and
the like, or a quaternary ammonium hydroxide such as

generally varying according to the age, Weight, and response
10

of the individual patient, as Well as the severity of the

tetramethylammonium hydroxide, and the like.
The compounds and pharmaceutically acceptable salts of

patient’s symptoms.

the invention may be combined With pharmaceutically

pound is administered to a human patient undergoing treat

acceptable carriers, excipients, adjuvants, and the like, to
form pharmaceutical compositions. The pharmaceutical
compositions may comprise other physiologically tolerated
and/or bene?cial compounds. Suitable carriers may be solid,
such as binders and cutting agents conventional in the pill,
tablet and capsule forming arts, or liquid, such as solvents,
diluents and emulsi?ers conventional in the parenteral and
oral elixir compounding arts.

In one exemplary application, a suitable amount of com
ment for cancer. Administration occurs in an amount
15

of a mammal per day.

Compounds of the invention may be synthesiZed by
20

methods set forth beloW.

In particular, compounds of formula I may be synthesiZed

Pharmaceutical compositions comprising compounds of

by Scheme 1 or Scheme 2, as appropriate.
The compounds of formulae III and 11 can be obtained
via Scheme 1.

the invention or pharmaceutically acceptable salts thereof

advantageously contain 0.01% to 100% by Weight of the
compound or a pharmaceutically acceptable salt of the
invention, preferably 0.1% to 50%, and even more prefer
ably 1 to 25%.

betWeen about 0.1 mg/kg of body Weight to about 20 mg/kg
of body Weight of a mammal per day, preferably of betWeen
0.5 mg/kg of body Weight to about 10 mg/kg of body Weight

25
Scheme 1

The compounds of this invention inhibit farnesyl-protein
transferase and the farnesylation of the oncogene protein

\
\
OAc
W
7

Ras. These compounds are useful as pharmaceutical agents 30

for mammals, especially for humans. These compounds may

1(a)

be administered to patients for use in the treatment of cancer.

Examples of the type of cancer Which may be treated With
the compounds of this invention include, but are not limited

to, colorectal carcinoma, exocrine pancreatic carcinoma, and
myeloid leukemias.

35

step (a)

O

8

\

\

\

OAC

The compounds of this invention may be administered to

mammals, preferably humans, either alone or, preferably, in

lo)

combination With pharmaccutically-acceptable carriers or

diluents, optionally With knoWn adjuvants, such as alum, in
a pharmaceutical composition, according to standard phar
maceutical practice. The compounds can be administered

orally or parenterally, including intravenous, intramuscular,
intraperitoneal, subcutaneous and topical administration.
For oral use of a chemotherapeutic compound according
to this invention, the selected compounds may be
administered, for example, in the form of tablets or capsules,

40

R2

45

R3

R1

IFU\/\)\/\9
\
\
OAc
N

R5
R4

or as an aqueous solution or suspension. In the case of tablets

led)

for oral use, carriers Which are commonly used include
lactose and corn starch, and lubricating agents, such as 50
magnesium stearate, are commonly added. For oral admin

istration in capsule form, useful diluents include lactose and
dried corn starch. When aqueous suspensions are required
for oral use, the active ingredient is combined With emul

sifying and suspending agents. If desired, certain sWeetening

R1

step (c,d)

I'm

R2

N

R3

R5

10
\

\

C1

55

and/or ?avoring agents may be added. For intramuscular,
intraperitoneal, subcutaneous and intravenous use, sterile
solutions of the active ingredient are usually prepared, and

R4

the pH of the solutions should be suitably adjusted and
buffered. For intravenous use, the total concentration of
solutes should be controlled in order to render the prepara
tion isotonic.
The present invention also encompasses a pharmaceutical

step (b)

60

1(6)
(III)

\f)
11

step (e,f)

composition useful in the treatment of cancer, comprising
the administration of a therapeutically effective amount of 65 Wherein formula R1—R6, III and 11 are as de?ned above.

the compounds of this invention, With or Without pharma
ceutically acceptable carriers or diluents. Suitable compo

Additionally, the compound of formula III may be reacted
With iodobeads to form the para-iodoaniline compound

US 6,284,910 B1
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14

(reaction step (g), not depicted above). When a compound of
formula III, Wherein R1, R2, R3, R4, R5, and R6 are H, the
product of such reaction step (g) is the compound 3 (8-(4

Scheme 2

iodoaniline)-3,7-dimethyl-2,6-octadiene pyrophosphate).

HO

Wk]

Reaction Conditions for Scheme 1

p = 1-10

J41)

(a) tert-butylhydroperoXide, SeO2, salicylic acid, CH2Cl2;

step (a)

R1

(b) the unsubstituted or substituted aniline:
R2

R1
R2

0%

I|§6

15

P c1

N\H

R3

R5

15
R4

R3

R5

law)

R4

step (b,c,d)

R1
R2

16
O

Wherein R1—R6 are as indicated in formula III, above,

P

NaBH(OAc)3, HOAc, 1,2-dichloroethane;
R3

O

R5

25

(c) K2CO3, MeOH, H2O;
(d) (Ph)3PCl3, Hunig’s base, CH3CN;

R4

let)

(f) N-(tert-butoXy carbonyl) cysteine methyl ether;

step (6.4)

R1

(g) iodobeads.
Compounds of formula III are based on a geranyl skeleton

R2

Where the terminal isoprene unit of the farnesyl moiety has
been replaced by an anilino functional group. Species 1
through 6 above are siX eXamples of molecules that have
been synthesiZed by the process of Scheme 1. Such com

O

P

R3

35

R4

iodoanilino, para-nitroanilino, para-aZidoanilino,

lob)

penta?uoroanilino, and para-aZidotetra?uoroanilino groups.
The methodology for synthesiZing substituted anilino ana
logs of FPP is robust and versatile. The aniline ring system
in these analogs provides a platform for the introduction of
a Wide variety of functional groups and provides a heteroa

R2

O
45

R3

14 p=3

P

\

OPP

Wherein RP—R5 are as de?ned above for formula V; and

suitable choice of p Will yield a compound of formula V, VI
or VII.

In formula 17, R8 is an hydroXy protecting group.
Scheme 2 Reaction Conditions

anilines With very sensitive functional groups such as aryl

(a) benZyl chloride;

aZides into the analogs. Previously reported methods to form
55

liZes modi?ed published procedures (75) to convert the
allylic alcohol to the corresponding allylic chloride using

(b) NaOH, ethyl acetoacetate;
(c) NaOH;
(d) H2504;
(e) ethyl diisopropylphosphonoacetate, NaH;
f) LAH;
(g) (Ph)3PCl2, Hunig’s base, CH3CN;
Compounds of formula V are based on an alkyl allylic

pyrophosphate skeleton Where the middle isoprene unit of

dichlorotriphenylphosphorane (9%10). The resulting allylic

farnesyl moiety is replaced by a variable length aliphatic

chloride Was then converted to the desired pyrophosphate

Compounds of formula V, VII and VII may be synthesiZed

M (V) 13 EPZZ;

R4

Reductive amination of ot-[3 unsaturated aldehydes to
form anilines has not been previously described in the
literature. The invention provides for incorporation of

by folloWing Scheme 2.

R5

12 <p=1>

The amino linkage is formed by reductive amination of

analog 1 and the prenyl-analog-cysteine (AG-cys) 11.

Step (sh)

R1

the aniline by the geranyl ot-[3 unsaturated aldehyde (8) With
NaBH(OAc)3 to form the lipid portion of the analog 9.

this linkage either do not Work or destroy sensitive func
tional groups. The presence of the amine precluded the
implementation of standard methods (72—74) to convert the
lipid allylic alcohol to the desired pyrophosphate via an
activated chloride intermediate. The present invention uti

0R8

R5

pounds possess Widely varied functionality, including para

tom linkage connecting the geranyl pyrophosphate moiety to
the phenyl group Which replaces the terminal isoprene unit.

\
M
17

hydrocarbon chain and the terminal isoprene unit is replaced
65

by either an anilino or a benZyl ether function. These
molecules can adopt a greater range of conformations rela

tive to the geranyl type analogs because there are feWer

US 6,284,910 B1
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This pathWay is especially advantageous When the groups

unsaturated bonds in the molecules. In addition, the overall

length of the molecule can be adjusted in single methylene

R1—R5 on the benZyl group are not stable to the LAH

increments by changing the length of the hydrocarbon

reduction to produce the alcohol.
This pathWay may also be used to produce compounds of
the formula IX by modifying reaction Scheme 3A. The
suitable starting materials, Which are modi?ed forms of 17

linker. Three examples of these molecules With different

lengths of hydrocarbon linker have been synthesiZed per
Scheme 2, taking advantage of all the synthetic lessons

above, may be produced by the method of Scheme 2,
Wherein compounds of formula: HOCH2CH2(OCH2CH2)

learned in the creation of the ?rst class of analogs. The
length of the hydrocarbon linker chain is set by the choice

of benZyl protected uu-chloro-alkanols 15 used to synthesiZe
the key intermediate ketone 16. This ketone is elaborated to
the trans-isoprenoid like allylic alcohol 17 by a Horner

10

Emmons reaction, folloWed by reduction of the resulting
ester With lithium aluminum hydride
AWide variety

of benZyl protecting groups (benZyl, p-bromobenZyl,
p-methoxybenZyl, etc.) are stable to this series of reactions
and these alcohols can be converted to the corresponding
pyrophosphates via the chloride. The ?rst example 12 is

tCl (t is 1—5) are substituted for the compound of formula
HOCH2(CH2)pCl in Scheme 2. The resulting modi?ed ana
log of 17 is then subjected to the steps outlined in Scheme
3A to produced IX.
Compounds of formula VI and VII may be produced by
the alternate pathWay described in Scheme 3B.
Scheme 3B

15

transferred to dansyl peptide by FTase With sloW kinetics,
shoWing that this class of analogs represents viable struc
tures for exploring the role of prenyl groups in biological
systems.
Compounds of formula VIII can be made by modifying
the process of Scheme 2 by substituting compounds of the

general formula HO—CH2—(OCH2CH2)PCl for HOCH2
(CH2)pCl in the ?rst step of scheme 2.
Compounds of formula X may be prepared as depicted in

25

reduction

HZOAtm)
Pd/C

Scheme 3A.
Scheme 3A
HO

Starting Material:

Mom;

R1

R2

0

MA
“

R3

lOBZ

\

Wherein OBZ is optionally substituted by R1—R5
0R8

17

R4

35

R5
R3

R5

R4

Remove OBZ group

R2

HZOAtm)

j Pd/C

0

MOM
\

R1

HOW
u

Oxidize

_

1. K2CO3, MeOH, H20

2. (Ph)3PCl3, Hunig's base, CH3CN
3. [(l'kblltyDzNh, HP207, CH3CN

0R8

45

_

lSWern Oxidation

pyrophosphorylation
R4

o

WW8

R3

1. K2CO3, MeOH, H20

R5

OW

R2

2. (Ph)3PCl3, Hunig's base, CH3CN
3. [(l'kblltyDzNh, HP207, CH3CN

q

OPP

(VI)

R1

55

Reductive amination and pyrophosphorylation to form product X

This pathWay is especially advantageous When the groups

R1

R2

R3

R1—R5 on the benZyl group are not stable to the LAH

reduction to produce the alcohol.
This pathWay may also be used to produce compounds of
the formula VIII by modifying reaction Scheme 3B. The
suitable starting materials, Which are modi?ed forms of 17

R5

NVW
|

R4

.

above, may be produced by the method of Scheme 2,
Wherein compounds of formula: HOCH2CH2(OCH2CH2)
[Cl (t is 1—5) are substituted for the compound of formula

OPP (X)

R6

65

Wherein R1—R6, u, and OPP arc as de?ned above in formula

X and R8 is an hydroxy protecting group.

HOCH2(CH2)pCl in Scheme 2. The resulting modi?ed ana
log of 17 is then subjected to the steps outlined in Scheme
3B to produce VIII.

US 6,284,910 B1
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The compounds of formula XIII can be obtained from a

spectra Were obtained in CDC13 (unless otherWise noted) at

compound of formula VI via the pathway of Scheme 4.

200 MHZ With a Varian XL200 spectrometer, or at 500 MHZ
With a Varian INOVA instrument. Chemical shifts for the

folloWing deuteriated solvents are reported in ppm doWn

M

?eld using the indicated reference peaks: CDCl3 (CDCl3
internal peak, 7.27 ppm for 1H, 77.4 ppm for 13C), D2O
(TSP, 0 ppm), CGH6 (CGH6 internal peak, 7.37 ppm for 1H).

R4

R3

R5

Mass spectra Were obtained With a HeWlett Packard 5890
Series II gas chromatograph With a 5972 series mass selec

O

R2

\
VWOPP
v1

10

R1

tive detector. Combustion analyses Were performed by
Atlantic Microlabs, Inc. Norcross, Ga.

(E,E)-3,7-Dimethyl-1-acetoXyl-2,6-octadien-8-al (5)
H2(1 Atm)
Pd/C

15

reduction

Geranyl acetate Was oXidiZed as described previously

With some modi?cation (21). Forty milliliters (0.36 mol) of
90% tert-butyl hydroperoXide Was added to a stirred sus

HO

pension of 1.11 g (0.01 mol) of SeO2, 1.4 g (0.01 mol) of

VWOH (XIII)

salicylic acid, and 75 ml of CH2Cl2 in a 250 ml round
bottom ?ask covered in aluminum foil. The resulting solu
tion Was alloWed to stir to homogeneity at room temperature

Wherein R1—R5 are as de?ned in formula VI above; Z is

1 to 10 and OPP is the pyrophosphate group.

before being placed at 0° C. After ten minutes, 21.5 ml (0.10
mol) of geranyl acetate (4) Was introduced dropWise. The

The corresponding compounds of formula XII may be
obtained from the compounds of formula VI by removing
the benZyloXy group via mild hydrogenolysis.

TLC analysis indicated the presence of starting material and

mixture Was stirred for 5 h at 0° C., and then for 20 h at rt.
25

The compounds of formula XI can be obtained by block

tWo oXidiZed products (Rf 0.38 aldehyde, Rf 0.19 alcohol).
The solution Was diluted With 100 ml toluene, and solvents

ing the terminal OH group, converting the 1-hydroXy group

Were removed under reduced pressure. The residue Was then

to the chloride, subjecting the same to pyrophosphorylation

dissolved in toluene, Washed With 5% NaHCO3 to remove

and ?nally removing the terminal OH group.

H2SeO3, saturated CuSO4, saturated aqueous Na2S2O3 (2><),
Water, brine, dried over MgSO4 and ?ltered. The solvent Was
removed under reduced pressure affording a crude oil, Which
Was dissolved in 100 ml dry CH2Cl2 and cooled to 0° C.

DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENTS

40.95 g (0.47 mol) of activated MnO2 Was added, and the

FPP,
General
15 Ci/mmol)
Methods—[1-3H]farnesyl
and [1-3H]geranylgeranyl
pyrophosphate
pyrophosphate

35

([3H]GGPP, 15 Ci/mmol) Were obtained from American
Radiochemical Co. Recombinant Wild-type p2lHa'ms pro
tein (p21H'mS CVLS) and its derivative p21H'mS CVLL Were
produced in bacteria as described previously (19).

Geranylgeranyl-cysteine (GG-Cys) and farnesyl-cysteine

colorless oil; 1H NMR (C6H6, 200 MHZ) 69.47 (s, 1H), 5.98
(t, 1H, J=6.9 HZ), 5.48 (t, 1H, J=6.9 HZ), 4.75 (d, 2H, J=6.8
HZ), 2.11 (q, 2H, J=7.3 HZ), 1.92 (t, 2H, J=7.3 HZ), 1.91 (s,

commercial sources.
45

eXcept as noted. Reaction temperatures refer to the eXternal

3H), 1.79 (s, 6H), 1.59 (s, 3H); 13C NMR (50.3 MHZ)
6195.47, 171.39, 153.70, 140.73, 140.08, 120.01, 61.48,
38.13, 27.33, 21.37, 16.77, 9.62.

(E,E) -8 -Aniline -3,7-dimethyl- 1 -acetoXyl-2,6
octadiene (6)

bath temperatures. All reactions and ?ash chromatography
procedures Were conducted under diminished light. Analyti
cal TLC Was performed on precoated (0.25 mm) silica gel
60F-254 plates purchased from E. Merck and developed
With 30% ethyl acetate in hexane, eXcept Where noted
otherWise. Preparative TLC Was performed on precoated

silica gel plates

The miXture Was ?ltered over a short bed of Celite, and

Washed thoroughly With dry CH2Cl2. Solvent Was evapo
rated under reduced pressure to yield a crude, pale yelloW oil
Which Was puri?ed by ?ash chromatography on silica gel
(5% EtOAc in heXane) affording 10.68 g (51 %) of 5 as a

(F-Cys) Were synthesiZed as described by Kamiya et al. (20)
and puri?ed by preparative TLC. All other solvents and
chemicals Were reagent grade and purchased from standard
General Synthetic Chemical Procedures. All reactions
Were conducted under dry argon, and stirred magnetically

suspension Was stirred for 5 h at 0° C., then overnight at rt.

The reductive amination procedure of Abdel-Magid et al.
(22—25) Was modi?ed as folloWs. Into a 250 ml 3-neck ?ask

covered in aluminum foil Was introduced 150 ml of 1,2

dichloroethane, folloWed by 7.88 g (37.48 mmol) of 5, 3.76
ml (41.22 mmol) of fresh aniline, and 2.58 ml (44.89 mmol)

Merck #13793-7) purchased from

irradiation, anisaldehyde-sulfuric acid spray folloWed by

of glacial acetic acid. After stirring for thirty seconds at
room temperature, 11.12 g (52.47 mmol) of NaBH(OAc)3

heating, or treating the plates With a 5% ethanolic phospho

Was added. The solution Was stirred for 5 h at Which time

molybdic acid solution folloWed by heating. Flash chroma
tography Was performed on Merck silica gel 60 (230—400
mesh ASTM) purchased from VWR. All chromatographic

TLC analysis indicated no remaining starting material (Rf of
6 0.46). The reaction miXture Was quenched by pouring into

solvents Were purchased from VWR

M. Science—

product Was eXtracted With ether (3><75 ml), dried (MgSO4),

OMNISOLV High Purity Grade) and used as received.
Anhydrous acetonitrile Was purchased from Aldrich. Acti
vated MnO2 Was purchased from Fluka; all other reagents

cation by ?ash chromatography (10% EtOAc in heXane)

Alltech. VisualiZation Was achieved either by UV

Were either purchased from Aldrich or Alfa Aesar, unless
otherWise noted. IR spectra Were recorded as liquid ?lms
using a NICOLET® 560 ESP FTIR spectrometer. NMR

55

a separatory funnel containing 200 ml of 5% NaHCO3. The

and concentrated to give a pale yelloW, viscous oil. Puri?

yielded 9.15 g (85%) of a light-straW colored to colorless oil;
65

1H NMR (200 MHZ) 67.18 (m, 2H), 6.69 (m, 1H), 6.62 (m,
2H), 5.38 (m, 2H), 4.60 (d, 2H, J=7.2 HZ), 3.82 (s, 1H), 3.65
(s, 2H) 2.33—2.02 (m, 4H), 2.08 (s, 3H), 1.72 (s, 3H), 1.69

